Tailor-made Antibodies
and Tools for Life Science
Home|||||Technical Support

EAAT1 peptide cytoplasmic domain - 250-11P

EAATs are transmembrane proteins involved in the removal of extracellular glutamate
control peptide
Cat. No.: 250-11P
Amount: 100 µg
Price: $105.00
Cat. No. 250-11P 100 µg peptide, lyophilized. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Control peptides should be stored at -20°C when still lyophilized!
Applications
 
Immunogen Synthetic peptide corresponding to AA 522 to 541 from rat EAAT1 (UniProt Id: P24942)
Recommended dilution Optimal concentrations should be determined by the end-user.
Matching antibodies 250 113, 250 114, 250 116
Remarks

This control peptide consists of the synthetic peptide (aa 522 - 541 of rodent EAAT 1) that has been used for immunization. It has been tested in preadsorption experiments and blocks efficiently and specifically the corresponding signal in Western blots. The amount of peptide needed for efficient blocking depends on the titer and on the affinity of the antibody to the antigen.

Data sheet 250-11p.pdf
Cat. No.: 250-11P
Amount: 100 µg
Price: $105.00
Background
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system. After the release of glutamate from synaptic vesicles into the synaptic cleft during neurotransmission, excitatory amino acid transporters (EAATs) remove extracellular glutamate to avoid excitotoxic levels.
Five EAATs with differential expression patterns have been described so far: EAAT 1, also referred to as GLAST and SLC1A3, has neuroprotective potential following ischemia and is expressed by reactive astrocytes and activated microglia. EAAT 2 (GLT-1, SLC1A2) is the most abundant and primarily expressed in astrocytes. EAAT 3 / SLC1A1 is expressed in neurons and has also been shown to be involved in the uptake of extracelluar cysteine. EAAT 4 shows weak expression in the forebrain and high levels in Purkinje cells of the cerebellum. EAAT 5 has only been described for humans and is primarily expressed in the retina.
Protocols